Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava PK, Kosma VMPrognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324

Department of Pathology and Forensic Medicine, University of Kuopio, Finland.
The Journal of Pathology (Impact Factor: 7.43). 07/1997; 182(3):318-24. DOI: 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6
Source: PubMed

ABSTRACT Clinical follow-up data of 276 colorectal adenocarcinoma patients treated in Kuopio University Hospital between 1976 and 1986 and followed up for a mean of 14 years were analysed. The clinical findings were correlated with tumour-infiltrating lymphocytes (TILs) and with histological and quantitative factors including nuclear parameters and volume-corrected mitotic index. In univariate survival analysis, TNM classification, Dukes' stage, histological grade, and TILs were significant predictors of survival. TNM classification, Dukes' stage, and TILs also predicted recurrence-free survival. In multivariate analysis, TILs were an independent prognostic factor of survival in all cases, as well as in patients with T1-4N0-3M0 and T1-4N1-3M1. TILs also independently predicted recurrence-free survival. TILs can provide important prognostic information in colorectal cancer to be used in evaluating for adjuvant therapy in different tumour stages.

1 Follower
  • Source
    • "TILs were less numerous than in early stages (Dukes stages A and B) [21]. Follicular and paracortical hyperplasia in local lymphatic nodes are also an important prognostic factor in colorectal cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Impact of immune microenvironment in prognosis of solid tumors has been extensively studied in the last few years. Specifically in colorectal carcinoma, increased knowledge of the immune events around these tumors and their relation with clinical outcomes have led to consider immune microenvironment as one of the most important prognostic factors in this disease. In this review we will summarize and update the current knowledge with respect to this intriguing and complex new hallmark of cancer, paying special attention to infiltration by T-infiltrating lymphocytes and their subtypes in colorectal cancer, as well as its eventual clinical translation in terms of long-term prognosis. Finally, we suggest some possible investigational approaches based on combinatorial strategies to trigger and boost immune reaction against tumor cells.
    Clinical and Developmental Immunology 11/2011; 2011:174149. DOI:10.1155/2011/174149 · 2.93 Impact Factor
  • Source
    • "Effector CD8 + tumor-infiltrating lymphocytes (CD8 + TILs) are major mediators for host's antitumor immunity [1] [2] [3] [4] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The indoleamine 2,3-dioxygenase-(IDO-) mediated microenvironment plays an important role in tumor immune escape. However, the inhibitory effects of IDO on the CD8(+) tumour-infiltrating lymphocytes (CD8(+) TILs) in esophageal squamous cell carcinoma (ESCC) have not been clarified yet. Here, we found that the level of IDO expression in ESCC tumor specimens correlated with a reduction in the number of CD8(+) TILs. Patients with high IDO expression and a low number of CD8(+) TILs had significantly impaired overall survival time. IDO expression and functional enzyme activity in ESCC cell lines could be induced by IFNγ. When exposed to the milieu generated by IDO-expressing Eca109 cells, the CD8(+) TILs were suppressed in proliferation, and their cytolytic functions against target tumor cells were lost. These results suggested that impairing CD8(+) TIL functions by IDO expressed in ESCC possibly contributed to the finding that patients with higher IDO expression have more aggressive disease progression and shorter overall survival time.
    Clinical and Developmental Immunology 10/2011; 2011:384726. DOI:10.1155/2011/384726 · 2.93 Impact Factor
  • Source
    • "ual et al . ( 2006 ) Breast cancer Marrogi et al . ( 1997 ) ; Menegaz et al . ( 2008 ) Bladder cancer Sharma et al . ( 2007 ) Ovarian cancer Zhang et al . ( 2003 ) ; Sato et al . ( 2005 ) Esophageal cancer Schumacher et al . ( 2001 ) ; Cho et al . ( 2003 ) Colorectal cancer Jass ( 1986 ) ; Graham and Appelman ( 1990 ) ; Harrison et al . ( 1994 ) ; Ropponen et al . ( 1997 ) ; Baier et al . ( 1998 ) ; Naito et al . ( 1998 ) ; Dalerba et al . ( 2003 ) ; Diederichsen et al . ( 2003 ) ; Prall et al . ( 2004 ) ; Pages et al . ( 2005 , 2009 ) ; Galon et al . ( 2006 ) ; Salama et al . ( 2009 ) Renal cell carcinoma Nakano et al . ( 2001 ) Prostatic adenocarcinoma Vesalainen et al . ( 1994 ) ; Karja et al . ( 200"
    [Show abstract] [Hide abstract]
    ABSTRACT: The natural history of a tumor includes phases of 'in situ' growth, invasion, extravasation and metastasis. During these phases, tumor cells interact with their microenvironment and are influenced by signals coming from stromal, endothelial, inflammatory and immune cells. Indeed, tumors are often infiltrated by various numbers of lymphocytes, macrophages or mast cells. It is generally believed that the latter produce factors that maintain chronic inflammation and promote tumor growth, whereas lymphocytes may control cancer outcome, as evidenced in mouse models. In this study, we analyze data from large cohorts of human tumors, clearly establishing that infiltration of the primary tumor by memory T cells, particularly of the Th1 and cytotoxic types, is the strongest prognostic factor in terms of freedom from disease and overall survival at all stages of clinical disease. We review data suggesting that tertiary lymphoid structures adjacent to tumors and composed of mature dendritic cells (T and B cells organized as germinal centers) may be the site of an antitumor reaction. We propose an immune scoring based on the type, density and location of lymphocyte infiltrates as a novel prognostic factor for use in addition to tumor node metastasis staging to predict disease-free survival and to aid in decisions regarding adjuvant therapies in early stage human cancers.
    Oncogene 11/2009; 29(8):1093-102. DOI:10.1038/onc.2009.416 · 8.56 Impact Factor
Show more